US FDA Approves Sevenfact [coagulation factor VIIa (recombinant)-jncw] for adults and adolescents with haemophilia A or B and inhibitors

This medicine has been approved for the treatment and control of bleeding episodes occurring in people aged >/=12 years with haemophilia A or B with inhibitors (neutralising antibodies). The active ingredient is expressed in genetically engineered rabbits.


Biospace Inc.